Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Novavax Stock Hit a Fresh 52-Week Low Today


Shares of the recombinant-protein vaccine specialist Novavax (NASDAQ: NVAX) were down by a noteworthy 9.2% on heavy volume as of 9:55 a.m. ET on Thursday. As a result, the biotech's stock price hit a fresh 52-week low this morning. 

What's weighing on Novavax's shares today? Yesterday, J.P. Morgan analyst Eric Joseph reportedly cut his 12-month price target on the stock from $132 to $27 a share, citing the company's recent downward revision for its 2022 revenue forecast as a key reason for the far lower price target.

This dramatic downward price revision is particularly interesting because it implies that Novavax won't even meet Wall Street's most-pessimistic 2023 revenue estimate of $1.25 billion. Spelling this point out, biotech stocks rarely trade at under two times forward-looking sales, even in this dour market.

Continue reading


Source Fool.com

Like: 0
Share

Comments